Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.30 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.30 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940895 | 0.84 | — | — | |
| SCHEMBL657834 | 0.84 | JAK2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL3938533 | 0.82 | — | — | |
| SCHEMBL19064376 | 0.79 | IKBKB (0.35) | — | |
| SCHEMBL23930527 | 0.78 | GABRA5 (0.32) | — | |
| SCHEMBL30436957 | 0.78 | ESR1 (0.30) | — | |
| SCHEMBL23989452 | 0.78 | GABRA5 (0.31) | — | |
| SCHEMBL17883349 | 0.78 | POLB (0.38) | — | |
| SCHEMBL6619443 | 0.77 | DRD2 (0.34) | — | |
| SCHEMBL893319 | 0.75 | HTT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | CYP2C19 4378/4885LCK 3020/4885MAP2K3 3717/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | CYP2C19 4378/4885LCK 3020/4885MAP2K3 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.